Vitamin K2 and Artery Calcification: Is It Worth Taking Before the Science Is Settled?

If you have coronary artery calcification, you've probably heard an intriguing theory about vitamin K2:

K2 helps your body regulate calcium—and may help limit the buildup of calcium in your arteries.

For years, that idea was supported mainly by biology, laboratory research and smaller clinical studies.

Now the evidence has moved forward.

In 2026, two randomized clinical trials reported that vitamin K supplementation was associated with slower progression of coronary artery calcification.

That's meaningful.

But it doesn't answer the question many people actually want answered:

If I already have calcium in my coronary arteries, should I take K2?

The honest answer is:

We don't know yet.

But the evidence is now interesting enough that the question deserves serious attention.

Why K2 might matter

Vitamin K isn't one single substance.

Vitamin K1 is abundant in leafy green vegetables and is best known for its role in normal blood clotting.

Vitamin K2 refers to a group of related compounds called menaquinones. One form that has received considerable research attention is MK-7, or menaquinone-7.

Vitamin K is required to activate several proteins involved in calcium regulation.

One of the most interesting is matrix Gla protein, or MGP, which is produced in vascular tissue and helps inhibit abnormal calcification.

That provides a plausible biological reason vitamin K status could matter when calcium begins accumulating in arteries.

But the popular explanation—

"K2 puts calcium in your bones instead of your arteries."

—is much simpler than the actual biology.

Coronary artery calcification occurs as part of atherosclerotic plaque development. It isn't simply a matter of calcium circulating through the bloodstream and being directed toward either bones or arteries.

The real question is whether improving vitamin-K-dependent biology can actually change what happens inside diseased arteries.

And now we have some better evidence.

The earlier evidence was mixed

Before the new 2026 trials, the evidence was far from settled.

A 2023 systematic review and meta-analysis included 14 randomized controlled trials involving 1,533 participants. It found that vitamin K supplementation was associated with slower progression of coronary artery calcium.

But the researchers also noted that more rigorous trials were needed.

The studies were quite different from one another. Some used vitamin K1, others K2, and many involved people with diabetes or chronic kidney disease rather than people with established coronary artery disease.

So the reasonable conclusion at the time was:

Interesting biology. Some encouraging trial evidence. Not enough to know whether K2 actually slows coronary calcification in people with coronary artery disease.

Then came VitaK-CAC.

The VitaK-CAC trial

The VitaK-CAC trial, published in JAMA Cardiology in 2026, was the first of the two new trials to directly test K2 alone in people with symptomatic coronary artery disease.

The study was led by Liv M. Vossen, Peter W. de Leeuw, Leon J. Schurgers and colleagues at Maastricht University Medical Center and other Dutch institutions.

The researchers randomized 180 people, of whom 167 were included in the analysis, to receive either:

• 360 micrograms of MK-7 daily, or
• placebo

for two years.

These were not generally elderly participants. Their median ages were about 59 to 61 years, so the study is relevant to older adults but was not an older-adult-specific trial.

The participants already had symptomatic coronary artery disease and CAC scores between 50 and 400.

The study population also looked quite different from a typical health-conscious supplement user:

• About 78% were taking statins
• Roughly 70% were smokers
• All had visible coronary plaque

After two years, the K2 group had significantly less progression of coronary artery calcium than the placebo group.

That's an important finding.

But there's another detail that deserves to be front and center.

This wasn't an ordinary store-bought K2 capsule

The study used 360 micrograms of MK-7, supplied as the branded ingredient MenaQ7, originally from Nattopharma and now part of Gnosis by Lesaffre.

That's a relatively high dose compared with many commercially available K2 supplements.

And the study wasn't completely free of industry involvement.

Gnosis supplied the MK-7 tablets free of charge, and study author Leon Schurgers reported receiving grants from Gnosis outside the submitted work.

The investigators reported that the supplier had no role in the study's design, conduct, analysis or interpretation.

That's an important distinction.

Industry involvement doesn't make a study invalid.

But readers deserve to know about it when a study of a supplement uses a manufacturer's branded ingredient.

Then came DANCODE

The second major 2026 trial was the DANCODE trial, published in Circulation.

It was conducted in Denmark and included 398 adults with severe coronary artery calcification, defined as a CAC score of at least 400.

The median age was 71.

Participants received either:

• 720 micrograms of MK-7 plus 25 micrograms of vitamin D3 daily, or
• placebo

for 24 months.

The results again pointed in the same general direction.

The average increase in CAC was:

196 Agatston units in the K2+D3 group

versus

248 Agatston units in the placebo group.

The difference was statistically significant.

In a subgroup of 143 participants who underwent coronary CT angiography, progression of calcified plaque volume was also attenuated in the treatment group.

But noncalcified plaque volume did not differ between groups.

And there's an important limitation:

DANCODE tested K2 and vitamin D3 together.

So it cannot tell us how much of the effect came from K2, how much from vitamin D3, or whether the combination was responsible.

DANCODE also had industry involvement

The DANCODE trial was investigator-run, but Kappa, a company that produces vitamin K2, funded the study and supplied the K2 product.

The investigators reported that Kappa had no role in the study's methodology, analysis or interpretation.

Again, that doesn't invalidate the findings.

But it belongs in the story.

Are these really two independent populations?

Not quite as much as the headline might suggest.

VitaK-CAC was conducted in the Netherlands.

DANCODE was conducted in Denmark.

Both are northern European studies.

So rather than saying that two completely different populations produced the same result, it's more accurate to say:

Two investigator-run randomized trials in northern European populations produced findings pointing in the same general direction.

That's encouraging—but it doesn't tell us whether the result will apply equally to everyone.

And the doses are important

This is another place where supplement marketing can get ahead of the science.

VitaK-CAC used 360 micrograms of MK-7 daily.

DANCODE used 720 micrograms daily, together with vitamin D3.

Those are substantial doses.

A person buying a typical K2 supplement should not assume that whatever amount is in the bottle has been shown to produce the same effect.

The trials tested specific products and doses.

We don't yet know the ideal dose, whether more is better, or whether much smaller amounts would have the same effect.

Here's the really important problem: Does a lower calcium score mean fewer heart attacks?

This is where the story gets much more complicated.

Coronary artery calcium is a valuable marker of atherosclerotic disease and cardiovascular risk.

But CAC progression is a surrogate measurement.

The thing patients actually care about isn't their calcium score.

It's whether they have:

• fewer heart attacks
• fewer strokes
• fewer hospitalizations
• less cardiovascular death
• or longer, healthier lives

We don't have that evidence yet.

In fact, a JAMA Cardiology editorial published alongside the VitaK-CAC study was titled:

"Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?"

The authors specifically questioned whether CAC progression is an adequate endpoint for determining whether a treatment actually benefits patients.

That's not a minor technicality.

It's central to interpreting the K2 research.

Statins provide a fascinating example

Here's why we should be careful about assuming that slower—or faster—calcium progression automatically means better—or worse—heart health.

Statins clearly reduce cardiovascular events.

Yet studies have found that coronary calcium can continue to increase during statin treatment, and some research has found changes toward denser, potentially more stable calcium.

In other words, a treatment can improve cardiovascular outcomes without necessarily making the CAC score go down.

That tells us something important:

The amount of calcium visible on a CT scan isn't the whole story.

So if K2 slows the increase in CAC, that's interesting.

It may turn out to be clinically meaningful.

But we cannot skip the next step and assume that it means fewer heart attacks.

What the new evidence does tell us

At this point, we can reasonably say:

Vitamin K plays a real biological role in regulating proteins involved in vascular calcification.

A 2023 meta-analysis of 14 randomized trials involving 1,533 analyzed participants found an overall association between vitamin K supplementation and slower CAC progression.

The 2026 VitaK-CAC trial found that 360 micrograms of MK-7 daily slowed CAC progression over two years in people with symptomatic coronary artery disease.

The 2026 DANCODE trial found that 720 micrograms of MK-7 plus vitamin D3 daily slowed CAC progression in people with severe coronary calcification.

Those are legitimate findings.

They're no longer just theoretical.

What we still don't know

We don't yet know whether taking K2:

• prevents heart attacks
• prevents strokes
• reduces cardiovascular deaths
• reverses existing coronary calcification
• removes calcium from established plaque
• improves survival
• or provides the same benefit at ordinary supplement doses

We also don't know whether K2 alone or K2 combined with vitamin D is the more important intervention.

And because both major 2026 trials were conducted in northern European populations, we need evidence from broader populations.

So should you take K2?

This is where the question gets genuinely interesting.

If someone asks:

"Has K2 been proven to prevent heart attacks?"

No.

If they ask:

"Is there now credible randomized evidence that vitamin K supplementation can slow progression of coronary artery calcification?"

Yes.

That's a much stronger statement than we could make a few years ago.

Whether an individual should take K2 is a separate question.

Someone with substantial coronary calcium may reasonably want to discuss the emerging evidence with their healthcare professional rather than simply dismissing K2 as supplement hype.

But neither should we treat K2 as established cardiovascular therapy.

And there is an especially important safety issue for people taking warfarin or another vitamin-K-sensitive anticoagulant: vitamin K can interfere with warfarin's effect, so supplementation should not be started or changed casually.

The bigger lesson

Science rarely moves from "we don't know" to "we know it works" overnight.

It usually happens in stages.

First comes a biological mechanism.

Then observational evidence.

Then small studies.

Then randomized trials.

Then larger trials that determine whether changing the measurement actually changes people's lives.

K2 appears to have moved another step along that path in 2026.

We now have moderate evidence that vitamin K supplementation can slow progression of coronary artery calcification.

We have limited evidence that this translates into better cardiovascular outcomes.

That's an important distinction.

The evidence is promising enough to watch.

It isn't strong enough to declare victory.

The Watchdog Takeaway

Vitamin K2 has moved from an intriguing theory toward something more substantial.

Two randomized clinical trials published in 2026 found that vitamin K supplementation slowed the progression of coronary artery calcification.

But the studies have important limitations.

VitaK-CAC was relatively small, involved mostly middle-aged rather than older adults, used a high dose of MK-7, and used a branded ingredient supplied by a K2 manufacturer.

DANCODE was larger and included people with severe coronary calcification, but it tested K2 plus vitamin D3, not K2 alone, and its K2 product was supplied by a K2 manufacturer that funded the study.

And both trials measured coronary calcium progression—not heart attacks or survival.

So should someone with coronary artery calcification take K2?

The science still doesn't justify a universal yes—or a universal no.

What it does justify is paying attention.

Don't dismiss K2 as hype. Don't call it proven heart protection. Watch the evidence.

That's where the science stands right now.